Related by context. All words. (Click for frequent words.) 77 hepatitis C genotype 73 HCV genotype 72 HCV genotypes 72 CCR5 tropic HIV 71 chronic HCV genotype 71 HCV infected 70 pegylated interferon 70 chronic HCV infection 69 chronic HCV 69 peginterferon 68 HCV SPRINT 68 lamivudine 68 plus ribavirin 68 HBeAg positive 68 ribavirin RBV 68 lamivudine refractory patients 67 chronic hepatitis C 67 ribavirin therapy 67 treatment naïve genotype 67 treatment naive genotype 67 LEXIVA r 66 pegylated interferon alfa 2a 66 virologic failure 66 hepatitis C HCV 66 PegIFN RBV 66 chlorambucil 66 peginterferon alfa 2a 66 PREZISTA r 66 protease inhibitor PI 66 null responders 66 Pegasys plus Copegus 66 genotype 1b 65 pegylated interferon alpha 65 peginterferon alfa 2b 65 metastatic renal cell carcinoma 65 #mg QD [002] 65 refractory CLL 65 TMC# C# 65 achieve sustained virologic 65 heavily pretreated 65 nucleoside naive 65 HCV RESPOND 2 64 PegIFN 64 sustained virologic response 64 pegylated interferon alfa 64 ritonavir boosted 64 HBeAg negative 64 virologic response 64 HCV 64 BARACLUDE ® 64 ribavirin 64 leukemia CLL 64 mRCC 64 peg IFN 64 HBeAg positive patients 64 recurrent glioblastoma multiforme 64 lopinavir r 64 pegylated alpha interferon 64 antiretroviral naive 64 null responder HCV 64 HBeAg seroconversion 64 achieved sustained virological 64 nitazoxanide 64 seronegative 63 PREZISTA ritonavir 63 virus HCV infection 63 virological response 63 antiretroviral naïve 63 relapsed MM 63 metastatic RCC 63 interferon alfa 63 linezolid 63 LTBI 63 severe neutropenia 63 stage IIIB 63 abacavir lamivudine 63 Peg IFN 63 darunavir ritonavir 63 evaluable subjects 63 COPEGUS ribavirin 63 alfa 2a 62 KRAS mutations occur 62 dasatinib Sprycel ® 62 alpha 2b 62 APTIVUS r 62 candidemia 62 posaconazole 62 naive HCV 62 undetectable viral load 62 enfuvirtide 62 telaprevir dosed 62 transcriptase inhibitor NNRTI 62 mCRC patients 62 TMC# [001] 62 viral kinetics 62 fludarabine 62 sustained virological response 62 entecavir 62 PREZISTA rtv 62 imipenem 62 3TC lamivudine Epivir 62 dacarbazine 62 pegIFN 62 FOLFIRI 62 HCV infection 62 NRTI 62 log# reduction 62 amoxicillin clavulanate 61 leukemia AML 61 chronically infected 61 plus dexamethasone 61 coinfected 61 micafungin 61 coinfected patients 61 HBeAg + 61 patients coinfected 61 unresectable stage 61 APTIVUS 61 DEB# 61 achieved sustained virologic 61 Hepatitis C virus HCV 61 REYATAZ r 61 ceftazidime 61 TMC# r 61 virologically suppressed 61 NNRTIs 61 tipranavir ritonavir 61 naïve HCV 61 CR nPR 61 dosing cohorts 61 evaluable 61 ertapenem 61 chronic HBV infection 61 virologic 61 autoantibody positive 61 FluCAM 61 NNRTI 61 recurrent GBM 61 relapsed refractory multiple myeloma 61 rapid virologic response 61 HBeAg 61 advanced NSCLC 61 pegylated interferons 61 oral vancomycin 61 Pegasys ® 61 naive HCV genotype 61 ACTEMRA TM 60 interferon alfa 2a 60 doripenem 60 docetaxel Taxotere ® 60 adefovir 60 lopinavir 60 rituximab refractory 60 interferon ribavirin 60 darunavir 60 virologic suppression 60 Ribavirin 60 invasive aspergillosis 60 immunocompetent 60 achieve sustained virological 60 evaluable patients 60 null responder 60 Peginterferon 60 HCV Genotype 60 mcg albinterferon alfa 2b 60 pegylated interferon alfa 2b 60 NNRTI resistant virus 60 Chronic Hepatitis C 60 bendamustine 60 superficial bladder cancer 60 mg ustekinumab 60 NNRTI resistance 60 NRTI resistance 60 biochemical relapse 60 tenofovir emtricitabine 60 chronic hepatitis B. 60 nucleoside analogue 60 rilpivirine 60 active comparator 60 low dose cytarabine 60 polymerase inhibitor 60 interferon therapy 60 chronic hepatitis C. 60 Flu Cy 60 HBeAg negative patients 60 celgosivir 60 Doxil ® 60 metastatic malignant melanoma 60 dacarbazine DTIC 60 sorafenib Nexavar ® 60 mg RDEA# 60 copies ml 60 castration resistant prostate cancer 60 tenofovir disoproxil fumarate 60 fluconazole 60 cell lymphoma CTCL 60 trabectedin 60 asymptomatic metastatic 60 refractory NSCLC 60 Copegus ® ribavirin 60 CMV disease 59 CCR5 antagonist 59 voriconazole 59 hepatitis C virus 59 decitabine 59 PEG interferon 59 decompensated liver disease 59 undetectable HCV RNA 59 recurrent genital herpes 59 trastuzumab Herceptin R 59 Copegus ribavirin 59 dose cohorts 59 piperacillin tazobactam 59 symptomatic BPH 59 HIV coinfected 59 erlotinib Tarceva ® 59 VELCADE melphalan 59 virologically 59 virological failure 59 virus HCV protease inhibitor 59 raltegravir 59 plus COPEGUS 59 caspofungin 59 chronic HBV 59 imatinib Gleevec ® 59 follicular lymphomas 59 inhibitor RG# 59 CCR5 tropic 59 HIV uninfected 59 NRTIs 59 certolizumab 59 virus HCV 59 nonresponders 59 8mg/kg 59 ceftriaxone 59 VFEND 59 peginterferon ribavirin 59 seroconversion 59 lopinavir r arm 59 ug dose 59 refractory AML 59 peginterferon alpha 2a 59 Naive Patients 59 daunorubicin 59 refractory multiple myeloma 59 forodesine 59 NRTI backbone 59 stage IIIB IV 59 recurrent NSCLC 59 RRMS patients 59 efavirenz EFV 59 viral suppression 59 atazanavir ritonavir 59 seroprotection 59 metastatic GIST 59 radezolid 59 refractory chronic myeloid 59 cEVR 59 mg kg dose 59 Tipranavir 59 undetectable viral loads 59 free survival PFS 59 peginterferon alfa 59 ritonavir boosted lopinavir 59 e antigen HBeAg 59 DENV 59 pegylated interferon ribavirin 59 mg QD 59 FOLFOX4 59 Raptiva r 59 sunitinib Sutent ® 59 copies mL 59 mapatumumab 59 metastatic hormone refractory 59 T#I mutation 59 S. aureus infections 59 FOLFIRI alone 59 achieved ACR# 59 oral allopurinol 59 peg interferon 59 invasive candidiasis 59 microbiologically evaluable 58 docetaxel chemotherapy 58 mg/m2 dose 58 randomized #:# 58 heavily pretreated patients 58 interferon alfa 2b 58 relapsing MS 58 hepatitis C virus HCV 58 FOLFOX 58 Elitek 58 tipranavir 58 dose cytarabine 58 cART 58 genotype 58 nonnucleoside reverse transcriptase inhibitor 58 IFN alfa 58 complete remissions 58 ascending doses 58 plus methotrexate 58 CDAD 58 genotypic resistance 58 viremia 58 infliximab monotherapy 58 invasive fungal infections 58 ritonavir boosted atazanavir 58 nucleoside analog 58 vicriviroc 58 M#V mutation 58 HCV infections 58 relapsed SCLC 58 μg dose 58 receiving VICTRELIS 58 partial remissions 58 HBV DNA 58 #mg BID [003] 58 PEGINTRON TM 58 EGFR mutations 58 peginterferon alfa 2a #KD 58 COMBIVIR 58 Peginterferon Alfa 2a 58 relapsed AML 58 tigecycline 58 lopinavir ritonavir 58 HCV RNA 58 locoregional disease 58 splenectomized patients 58 oropharyngeal candidiasis OPC 58 mcg dose 58 INVANZ 58 adriamycin 58 gemcitabine 58 seropositive patients 58 prostate cancer HRPC 58 TDF FTC 58 nucleotide analogue 58 nelfinavir 58 histologically confirmed 58 CMV infection 58 remission induction 58 mg BID 58 elvucitabine 58 recurrent glioma 58 tenofovir FTC 58 CML CP 58 receiving INTRON 58 bevirimat 58 anthracyclines taxanes 58 unresectable 58 KRAS mutant tumors 58 SCH # 58 #mg BID [001] 58 T2DM 58 Traficet EN 58 gefitinib 58 administered subcutaneously 58 CHOP chemotherapy 58 nevirapine Viramune 58 5-FU/LV 58 infliximab 58 carboplatin paclitaxel 58 seroconverted 58 efavirenz Sustiva 58 gemcitabine carboplatin 58 CANCIDAS 58 transcriptase inhibitors 58 sorafenib Nexavar 58 REYATAZ r arm 58 TKI therapy 58 underwent resection 58 comparator arm 58 Gleevec resistant 58 LPV r 58 bortezomib 58 4mg/kg 58 PEG IFN 58 Aptivus ® 58 antiviral therapy 58 experienced virologic failure 57 viral load 57 stage IIIb IV 57 highly emetogenic 57 trastuzumab Herceptin ® 57 mg qd 57 antiviral activity 57 evaluating tivozanib 57 darunavir r 57 CC genotype 57 anthracycline containing 57 tipranavir r 57 Reverset 57 cIAI 57 lamivudine monotherapy 57 pegylated interferon alpha 2a 57 Pharmacokinetics PK 57 chronic lymphocytic leukemia CLL 57 q8h 57 zidovudine AZT 57 CIMZIA TM 57 idarubicin 57 biologic DMARD 57 imatinib resistant 57 relapsers 57 fluconazole resistant 57 meropenem 57 Fludara 57 HBV DNA levels 57 placebo dexamethasone 57 IU mL 57 recurrent VTE 57 Albuferon TM 57 irinotecan chemotherapy 57 cidofovir 57 microbiological eradication 57 REBETOL 57 sorafenib 57 immunosuppressed patients 57 cytogenetic responses 57 prior chemotherapy regimens 57 non nucleoside reverse 57 oral ridaforolimus 57 progressive PsA 57 cutaneous T 57 receptor tyrosine kinase inhibitor 57 indinavir 57 HBsAg 57 grade cervical intraepithelial 57 IV NSCLC 57 virologic response EVR 57 pomalidomide 57 castrate resistant prostate cancer 57 P aeruginosa 57 KRAS wild 57 EGFR TKI 57 dexamethasone Decadron 57 Pegasys peginterferon alfa 2a 57 pegylated liposomal doxorubicin 57 immunomodulator 57 DMARDs 57 docetaxel 57 MabCampath 57 VICTRELIS 57 vancomycin 57 DLBCL 57 #mg BID [002] 57 basal cell carcinoma BCC 57 T#I [002] 57 BCG vaccinated 57 zidovudine lamivudine 57 K ras mutations 57 investigational protease inhibitor 57 NSCLC 57 alpha 2a 57 plus gemcitabine 57 PRTX 57 CCyR 57 methicillin resistant S. aureus 57 PegIntron 57 serum HCV RNA 57 HER2 positive metastatic breast 57 REYATAZ ® 57 mildly symptomatic 57 dosage regimens 57 dexamethasone 57 mcg BID 57 minimally symptomatic metastatic castrate 57 flutamide 57 Virologic 57 ethambutol 57 PEG Interferon alfa 57 log# copies mL 57 XIENCE V PROMUS Stent 57 viral loads 57 Hepsera 57 DOXIL 57 primary hypercholesterolemia 57 HBeAg negative chronic hepatitis 57 amodiaquine 57 nucleotide analog 57 QD dosing 57 oral rivaroxaban 57 TEAEs 57 beclomethasone dipropionate 57 mycophenolate mofetil 57 CIMZIA ™ 57 #mg/m# [001] 57 imatinib 57 fluvastatin 57 PRECiSE 57 cabazitaxel 57 imatinib Gleevec 57 n = 57 multidrug resistant 57 FLT3 mutations 57 ABC/3TC 57 relapsed refractory 57 CRp 57 minimally symptomatic 57 combination antiretroviral therapy 57 protease inhibitors PIs 57 disease modifying antirheumatic 57 myeloablative 57 adefovir dipivoxil 57 immunomodulatory therapy 57 resectable 56 telaprevir 56 pyrazinamide 56 chronic hepatitis B 56 clinically evaluable 56 advanced hepatocellular carcinoma 56 HPV-#/# 56 fosamprenavir 56 Infected Patients 56 abnormal cytology 56 Cethromycin 56 ZOLINZA 56 APTIVUS ritonavir 56 hematologic toxicity 56 Lamivudine 56 pancreatic NET 56 STELARA 56 imatinib therapy 56 lupus nephritis 56 dasatinib Sprycel 56 ABSSSI 56 genotype 1a 56 hepatocellular carcinoma HCC 56 baminercept 56 ISENTRESS 56 nucleoside analogues 56 K#N 56 Gag polymorphisms 56 recurrent glioblastoma 56 de novo kidney transplant 56 boosted protease inhibitor 56 lamivudine 3TC 56 R# #mg BID 56 undetectable hepatitis C 56 #mg q8h 56 Tamibarotene 56 DAPT 56 median PFS 56 fallopian tube carcinoma 56 relapsed CLL 56 lenalidomide Revlimid R 56 complete cytogenetic response 56 seropositive 56 clodronate 56 HIV RNA 56 blinded placebo controlled 56 gonococcal infections 56 lopinavir ritonavir Kaletra 56 oral prodrug 56 INTELENCE 56 glioblastoma multiforme GBM 56 ALT flares 56 gemcitabine Gemzar 56 anti TNF 56 interferon 56 FluCAM arm 56 plus prednisone 56 situ CIS 56 intramuscularly 56 TNF antagonist 56 mg TID 56 lymphocytosis 56 AZT zidovudine Retrovir 56 oral protease inhibitor 56 atazanavir 56 DMARD therapy 56 noninferiority 56 virologic responses 56 dasatinib 56 NS5B polymerase 56 Hepsera adefovir dipivoxil 56 locoregional 56 neoadjuvant chemotherapy 56 AVODART 56 mitomycin 56 prostate cancer CRPC 56 tuberculin skin testing 56 Blinatumomab 56 ZYVOX 56 HCD# [002] 56 infliximab therapy 56 liver histology 56 progression TTP 56 standard chemotherapy regimens 56 tyrosine kinase inhibitor TKI 56 AEG# 56 DU #b 56 valacyclovir 56 lung metastases 56 achieved PASI 56 Pegasys R 56 iPrEx study 56 omega interferon 56 prospectively defined 56 AGILECT R 56 CIMZIA TM certolizumab pegol 56 virus HBV 56 ovarian carcinoma 56 SCIg 56 PEGylated Fab fragment 56 DOXIL ® 56 HCV replicon 56 CYT# potent vascular disrupting 56 patients evaluable 56 Telbivudine 56 Epivir 56 % CI #.#-#.# [003] 56 IV metastatic melanoma 56 co trimoxazole 56 events AEs 56 cyclophosphamide methotrexate 56 histologies 56 ACR# response 56 telbivudine 56 atazanavir sulfate 56 Aflibercept 56 taxane chemotherapy 56 post herpetic neuralgia PHN 56 cilengitide 56 relapsing multiple sclerosis 56 moxifloxacin 56 mg q#h 56 nucleoside reverse transcriptase inhibitor 56 octreotide LAR 56 docetaxel Taxotere R 56 del 5q MDS 56 lamivudine zidovudine 56 androgen independent 56 chronic ITP patients 56 castrate resistant 56 CD8 responses 56 BMS # 56 randomized multicenter trial 56 cetuximab Erbitux R 56 Viramidine 56 rizatriptan 56 MCyR 56 investigational integrase inhibitor 56 untreated AML 56 doxorubicin docetaxel 56 trimethoprim sulfamethoxazole 56 mcg kg REBETOL 56 metastatic neuroendocrine tumors 56 multidrug resistant TB MDR 56 metastatic castration resistant 56 papillary renal cell carcinoma 56 saline placebo 56 uncomplicated malaria 56 myelodysplastic myeloproliferative diseases 56 Bezielle 56 anthracycline taxane 56 temsirolimus 56 superinfection 56 PEGINTRON 56 subcutaneously administered 55 RECIST criteria 55 blinded randomized placebo controlled 55 iclaprim 55 cisplatin vinorelbine 55 amprenavir 55 HIV HCV coinfected 55 azathioprine 55 VIRAMUNE XR 55 Ophena TM 55 cariprazine 55 sulfadoxine pyrimethamine 55 highly immunogenic 55 oral FTY# 55 evaluating REVLIMID 55 febrile neutropenia 55 dose escalation phase 55 immunosuppressed 55 vaccinees 55 neoadjuvant 55 Copegus ® 55 BENICAR HCT 55 antiviral efficacy 55 valopicitabine 55 adjunctive placebo 55 placebo PBO 55 doxorubicin HCl liposome injection 55 q#h 55 antiretroviral agents 55 liver metastases 55 definite stent thrombosis 55 sorafenib Nexavar R 55 PEG INTRON R 55 PROSTVAC VF 55 Pegylated interferon 55 acute GvHD 55 eosinophilic asthma 55 prostate cancer CaP 55 nab paclitaxel 55 RESIST studies 55 adalimumab 55 vinorelbine 55 relapsed refractory AML 55 mcg kg 55 alefacept 55 Extensively drug 55 MADRS score 55 immunocompetent patients 55 chronic plaque psoriasis 55 nucleoside 55 levofloxacin 55 esophageal candidiasis 55 efavirenz emtricitabine 55 plasma HCV RNA 55 mycophenolate mofetil MMF 55 sunitinib 55 indolent NHL 55 pancreatic adenocarcinoma 55 hypomethylating agents 55 ErbB2 positive 55 estramustine 55 pancreatic neuroendocrine tumors 55 NOXAFIL 55 sUA 55 median CD4 55 tenofovir DF 55 dosed orally 55 abacavir Ziagen 55 lymphoma CTCL 55 isoniazid 55 HBV genotype 55 CCR5 receptor antagonist 55 Myelodysplastic Syndrome MDS 55 ara C 55 genital HPV 55 serologically active systemic lupus 55 bortezomib Velcade R 55 VIR# 55 COU AA 55 metastatic renal cell 55 latent tuberculosis infection 55 severe renal impairment 55 COPEGUS 55 peginterferon alfa 2a Pegasys 55 metastatic HRPC 55 BR.# 55 Cytoxan 55 chemotherapeutic regimens 55 dose regimens 55 CrCl 55 everolimus tablets 55 relapsed multiple myeloma 55 ceftaroline 55 Engerix B 55 renal tumors 55 HCV NS5B polymerase 55 mcg mL 55 Pegylated Interferon 55 double blinded placebo 55 pegylated interferon peg IFN 55 azacitidine 55 cervical intraepithelial neoplasia 55 genital HSV 55 fistulizing Crohn disease 55 undetectable HBV DNA 55 adult chronic ITP 55 dapagliflozin plus 55 dapsone 55 serum HBV DNA 55 CLL SLL 55 antiretroviral regimens 55 monotherapy 55 BRAF mutation 55 Sustained Virologic Response 55 diabetic neuropathic pain 55 relapsing remitting multiple sclerosis 55 ketoconazole 55 receiving immunosuppressive therapy 55 alkylating agent 55 Gemzar ® 55 CsA 55 potent antiviral 55 FOLPI 55 trastuzumab 55 generation NNRTI 55 refractory CML 55 relapsed ovarian cancer 55 IU ml 55 Hepatitis B virus 55 leukopenia 55 antiviral prophylaxis 55 HAART regimen 55 imatinib mesylate Gleevec 55 adefovir treated 55 anti TNF alpha 55 standard chemotherapy regimen 55 stavudine d4T 55 nilotinib 55 hepatic metastases 55 postmenopausal osteoporotic women 55 chronic ITP 55 vWD 55 pegylated liposomal doxorubicin PLD 55 AZT 3TC 55 5FU 55 cells mcL 55 quinolone 55 FTC TDF 55 maximally tolerated dose 55 -#.# log# 55 EDEMA3 55 Nitazoxanide 55 cisplatin chemotherapy 55 novel VDA molecule 55 previously untreated follicular 55 Phase #/#a 55 VZV 55 Lymphocytic 55 EGFR mutation positive 55 suppressive therapy 55 XELOX 55 SVR# 55 cytogenetic response 55 pCR 55 budesonide foam 55 aldosterone antagonist 55 sulfasalazine 55 Median survival 55 clade B 55 Amigal 55 Neutropenia 55 mcg doses 55 OncoVEX GM CSF 55 NXL# 55 Aspergillus infections 55 NATRECOR ® 55 squamous histology 55 hepatocellular cancer 55 cetuximab Erbitux ® 55 refractory gout 55 lamivudine resistant 55 tinidazole 55 leukemia ALL 55 Copegus 55 detectable HCV RNA 55 HepC 55 azoles 55 Gilead Viread 55 HBV 55 tenofovir Viread 55 Plicera 55 PCa 55 IFN α 55 dose dose escalation 54 intravesical therapy 54 gastrointestinal stromal tumors 54 mitoxantrone 54 methotrexate monotherapy 54 Retreatment 54 FOLFOX regimen 54 chemoradiation 54 relapsing remitting MS RRMS 54 NS5b 54 antithymocyte globulin 54 fluticasone salmeterol 54 severe exacerbations 54 placebo controlled clinical trials 54 irinotecan containing 54 nilotinib Tasigna ® 54 plus OBT 54 gastrointestinal stromal tumors GIST 54 capecitabine 54 splenectomized 54 virologic breakthrough 54 R5 tropic 54 metformin monotherapy 54 rituximab 54 CAELYX 54 Hepatitis C virus 54 acute myelogenous leukemia AML 54 ano genital warts 54 receiving highly emetogenic 54 HGS ETR1 54 protease inhibitor telaprevir 54 orally bioavailable 54 KRAS mutations 54 refractory chronic lymphocytic 54 OHR/AVR# 54 HAART regimens 54 Phase 2a trial 54 follicular lymphoma 54 cisplatin gemcitabine 54 Neovascular AMD 54 Nilotinib 54 miconazole 54 colorectal liver metastases 54 HBV vaccine 54 serum phosphorus 54 riociguat 54 cobicistat 54 Velcade bortezomib 54 GvHD 54 platinum refractory 54 orally administered inhibitor 54 PROMACTA 54 protease inhibitor 54 -#.# log# copies mL 54 chemotherapy regimens 54 tolterodine ER 54 remission CR 54 somatostatin analog 54 plasma uric acid 54 invasive fungal infection 54 dose cohort 54 EPIVIR 54 nucleoside naive patients 54 BENICAR 54 anagrelide 54 advanced metastatic renal 54 weekly subcutaneous injections 54 amrubicin 54 transcriptase inhibitors NNRTIs 54 Aptivus 54 paroxysmal AF 54 prior relapsers 54 intravenous bisphosphonates 54 platelet inhibitor 54 Staphylococcus aureus MRSA 54 advanced adenomas 54 immunocompromised patients 54 plus Copegus R 54 TKIs 54 telaprevir pegylated interferon 54 Elvitegravir 54 Isentress raltegravir 54 cytarabine 54 elevated transaminases 54 methotrexate MTX 54 Lupuzor ™ 54 tuberculin skin test 54 CR CRu 54 indinavir Crixivan 54 NYHA Class II 54 HIV coinfection 54 HbA1c levels 54 chronic myeloid leukemia CML 54 sodium glucose cotransporter 54 emtricitabine FTC 54 bexarotene 54 herpes zoster shingles 54 emtricitabine tenofovir 54 amphotericin B 54 low dose ritonavir 54 bosentan 54 dose escalation study 54 mg Proellex 54 nonmetastatic 54 primary immunodeficiency PI 54 saquinavir ritonavir 54 BRAF V# mutation 54 completely resected 54 placebo controlled trials 54 huN# DM1 54 serum urate 54 sorafenib tablets 54 Darunavir 54 non splenectomized 54 Atripla combines 54 squamous cell histology 54 gemcitabine cisplatin 54 Sprycel dasatinib 54 nodular partial response 54 pertuzumab 54 Omacetaxine 54 antibody titers 54 CIN3 54 antiretroviral regimen 54 hepatitis B virus HBV 54 LymphoStat B belimumab 54 trials RCTs 54 erlotinib 54 toenail onychomycosis 54 combination REBETOL PEG 54 adverse cytogenetics 54 Chlamydia trachomatis 54 recurrent malignant glioma 54 bosutinib 54 apremilast 54 Boceprevir 54 single ascending dose 54 Xeloda ® 54 lenalidomide 54 mutated KRAS 54 metastatic lung cancer 54 coinfection 54 elvitegravir 54 non squamous NSCLC 54 melphalan prednisone 54 cyclophosphamide 54 liver transplant recipients 54 phase IIb study